Unknown

Dataset Information

0

Cationically modified inhalable nintedanib niosomes: enhancing therapeutic activity against non-small-cell lung cancer.

ABSTRACT: Aim: This study was designed to develop and test nintedanib-loaded niosomes as inhalable carriers for enhancing its therapeutic efficacy via localized drug accumulation and addressing issues such as low bioavailability and severe toxicity. Methods: Niosomes were prepared by thin-film hydration method and were evaluated for in vitro therapeutic effectiveness in lung cancer cells. Results: The optimized niosomal formulation displayed optimized vesicle size, controlled and extended release of drug, and efficient aerodynamic properties indicating its suitability as an aerosolized formulation. In vitro studies revealed significantly superior cytotoxicity of nintedanib-loaded niosomes which was further validated by 3D spheroids. Conclusion: These findings establish the effectiveness of niosomes as inhalable delivery carriers which could serve as a promising strategy for delivery of nintedanib to treat several lung cancers.

SUBMITTER: K Shukla S 

PROVIDER: S-EPMC9583758 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Cationically modified inhalable nintedanib niosomes: enhancing therapeutic activity against non-small-cell lung cancer.

K Shukla Snehal S   Nguyen Veronica V   Goyal Mimansa M   Gupta Vivek V  

Nanomedicine (London, England) 20220601 13

<b>Aim:</b> This study was designed to develop and test nintedanib-loaded niosomes as inhalable carriers for enhancing its therapeutic efficacy via localized drug accumulation and addressing issues such as low bioavailability and severe toxicity. <b>Methods:</b> Niosomes were prepared by thin-film hydration method and were evaluated for <i>in vitro</i> therapeutic effectiveness in lung cancer cells. <b>Results:</b> The optimized niosomal formulation displayed optimized vesicle size, controlled a  ...[more]

Similar Datasets

Unknown Clinical development of nintedanib for advanced non-small-cell lung cancer.
| S-EPMC4654540 | biostudies-literature
Unknown Systematic Development and Optimization of Inhalable Pirfenidone Liposomes for Non-Small Cell Lung Cancer Treatment.
| S-EPMC7150896 | biostudies-literature
Unknown Therapeutic vaccines in non-small cell lung cancer.
| S-EPMC4928356 | biostudies-other
Unknown A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer
| S-EPMC11228753 | biostudies-literature
Unknown Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.
| S-EPMC5329017 | biostudies-literature
Unknown Development of a 5-FU modified miR-129 mimic as a therapeutic for non-small cell lung cancer.
| S-EPMC9995506 | biostudies-literature
Unknown Repurposing Bedaquiline for Effective Non-Small Cell Lung Cancer (NSCLC) Therapy as Inhalable Cyclodextrin-Based Molecular Inclusion Complexes.
| S-EPMC8124211 | biostudies-literature
Unknown Therapeutic vaccines for advanced non‐small cell lung cancer
| S-EPMC6673723 | biostudies-literature
Unknown Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity.
| S-EPMC10449572 | biostudies-literature
Unknown Metallodrugs in the battle against non-small cell lung cancer: unlocking the potential for improved therapeutic outcomes.
| S-EPMC10506097 | biostudies-literature